• 2017

    Nominated as deputy director of Testing Equipment Material and Component Specialized Committee, Chinese Association of Medical Device Industry.

    Obtained ISO9001:2015 international quality management system certification.


  • 2016

    Listed in new OCT market,stock ticker: 838391.

    Brand new industrial base completed, company shifted to Songshan Lake, Dongguan.


  • 2015

    Sales growth rapidly, the success of broken billion

    Completed the recombinant monoclonal antibody platform.


  • 2014

    Completed construction of POCT fluorescent quantitative platform.

  • 2013

    Completed construction of in vitro fermentation antibody production platform.

  • 2012

    Native M. tuberculosis proteins listed in Provincial Key New Products.

  • 2011

    The  research and industrialization of new generation HAV reagents was listed in the National Torch Plan.

    Completed the construction of polyclonal antibody platform.


  • 2010

    The research and industrialization of  new generation HCV diagnostic reagents was listed in the National Torch Plan.

    The new generation HIV ELISA reagents was listed in the National Key New Products Program.

    Completed constructio of molecular diagnostic platform.


  • 2009

    Won "Guangdong Province Key New Product" honor

    Shenzhen Scientific Innovation Award.

    Guangdong Province Science and Technology Progress Award.

    Approved as national high-tech enterprise.


  • 2008

    Obtained ISO9001:2000 quality management system certification.

    Obtained innovation fund for small and medium-sized technology-based firms; 

    Won a championship in the first Shenzhen Nanshan “Entrepreneurship Star”contest.

    Completed the construction of  CG-ICA(colloidal gold immunochromatographic assay) and monoclonal antibody platforms


  • 2007

    Obtained an innovation fund from Ministry of  Science and Technology

    Entered the international market.


  • 2006

    Approved as Shenzhen high-tech enterprise.

  • 2005

    Upgraded the HIV recombinant antigen and developed HTLV recombinant antigen.

  • 2004

    The first developed HCV double-anigen sandwich ELISA kit and 2 PCT patents were granted.

    Launched monoclonal antibody platform.


  • 2003

    Sucessfully developed syphilis (TP) recombinant antigen.

  • 2002

    Approved as technology  innovation enterprise emphatically supported by Shenzhen municipal government.

    Successfully developd HIV antigen.


  • 2001

    Company Established.

    Set up ELISA and genetic engineering platforms.


  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001